Literature DB >> 20151335

Slippery platelet syndromes in subdural hematoma.

Paul Taylor Akins1, Kern Hayden Guppy, Kamran Sahrakar, Mark Wade Hawk.   

Abstract

BACKGROUND: This study investigates platelet dysfunction in patients with subdural hematomas (SDH) using platelet function analysis (PFA).
METHODS: PFA using the PFA-100 (Dade International Inc., Miami, FL) was performed at admission using the collagen-epinephrine and collagen-ADP assays in 58 SDH patients. Clinical and radiologic information was collected.
RESULTS: Normal PFA results were present in 36 patients (62%; PFA collagen:epinephrine assay (s) 118 ave; PFA collagen:adenosine diphosphate assay (s) ave 75) and abnormal platelet function in 22 patients (38%; PFA collagen:epinephrine assay (s) 231 average; PFA collagen:adenosine diphosphate assay (s) 124 average). Compared to patients with normal PFA results, patients with abnormal PFA results were more likely to have hypertension (22 vs. 55%; P = 0.01), take clopidogrel (3 vs. 32%; P = 0.001), and use anti-platelet medications and non-steroidal anti-inflammatory agents (22 vs. 59%; P = 0.004). Measurements of baseline CT for midline shift, maximum thickness, presence of blood/fluid levels in the hematoma, and presence of additional sites of intracranial bleeding did not reveal significant differences based on PFA testing. Platelet dysfunction improved after platelet transfusions (PFA collagen:epinephrine assay: baseline 270 s, CI 61 s; after transfusion 124 s, CI 50 s, P < 0.001).
CONCLUSION: Platelet dysfunction was found in 38% of SDH patients. This finding adds to our understanding of the pathophysiology of SDH. Since platelet transfusions are indicated for platelet dysfunction accompanied by major bleeding or need for surgery, these results impact peri-operative management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151335     DOI: 10.1007/s12028-010-9336-3

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  20 in total

1.  Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.

Authors:  Paul T Akins; Harvey A Feldman; Robert G Zoble; David Newman; Stefan G Spitzer; Hans-Christoph Diener; Gregory W Albers
Journal:  Stroke       Date:  2007-01-25       Impact factor: 7.914

Review 2.  Subdural hematoma in regularly hemodialyzed patients.

Authors:  A Leonard; F L Shapiro
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

3.  Description of an in vitro platelet function analyzer--PFA-100.

Authors:  S K Kundu; E J Heilmann; R Sio; C Garcia; R M Davidson; R A Ostgaard
Journal:  Semin Thromb Hemost       Date:  1995       Impact factor: 4.180

4.  Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen.

Authors:  Neil A Goldenberg; Linda Jacobson; Marilyn J Manco-Johnson
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

5.  Coagulopathy and outcome in patients with chronic subdural haematoma.

Authors:  S A König; U Schick; J Döhnert; A Goldammer; H-E Vitzthum
Journal:  Acta Neurol Scand       Date:  2003-02       Impact factor: 3.209

Review 6.  Platelet dysfunction in renal failure.

Authors:  Paola Boccardo; Giuseppe Remuzzi; Miriam Galbusera
Journal:  Semin Thromb Hemost       Date:  2004-10       Impact factor: 4.180

7.  Platelet activation and function after trauma.

Authors:  R C Jacoby; J T Owings; J Holmes; F D Battistella; R C Gosselin; T G Paglieroni
Journal:  J Trauma       Date:  2001-10

8.  The effects of nonsteroidal anti-inflammatory drugs on platelet function and severity of upper gastrointestinal haemorrhage.

Authors:  Semir Pasa; Kadim Bayan; Mehmet Kucukoner; Yekta Tuzun; Abdullah Altintas; Timucin Cil; Ramazan Danis; Orhan Ayyildiz
Journal:  J Thromb Thrombolysis       Date:  2008-08-12       Impact factor: 2.300

9.  Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage.

Authors:  Andrew M Naidech; Sarice L Bassin; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Paul F Lindholm; Thomas P Bleck
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

10.  Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time.

Authors:  G M Podda; P Bucciarelli; F Lussana; A Lecchi; M Cattaneo
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

View more
  5 in total

1.  The slippery slope of platelet transfusion for intracerebral hemorrhage.

Authors:  Wendy C Ziai; Marek A Mirski
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

2.  Desmopressin for the treatment of aspirin-induced platelet dysfunction.

Authors:  Sebastian Schulz-Stübner
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

3.  Initial Conservative Management of Severe Hemispheric Stroke Reduces Decompressive Craniectomy Rates.

Authors:  Paul T Akins; Yekaterina V Axelrod; Syed T Arshad; Kern H Guppy
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

4.  A 10-Year Analysis of 3693 Craniotomies during a Transition to Multidisciplinary Teams, Protocols, and Pathways.

Authors:  Paul T Akins; Amit Banerjee; Kern Guppy; James Silverthorn; John Fitzgibbon; Yogesh Nandan; Elaine O Yu; Luis Pacheco; Jack Rozance; Rob Azevedo; James Chang; Mark W Hawk
Journal:  Perm J       Date:  2019-10-18

5.  Platelet dysfunction is an early marker for traumatic brain injury-induced coagulopathy.

Authors:  Patrick K Davis; Harsha Musunuru; Mark Walsh; Robert Cassady; Robert Yount; Andrew Losiniecki; Ernest E Moore; Max V Wohlauer; Janet Howard; Victoria A Ploplis; Francis J Castellino; Scott G Thomas
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.